OSE Immunotherapeutics
A biotech company developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I).
The company is company developing novel immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation.
Latest OSE Immunotherapeutics News & Features
28 February 2024
14 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze